Stopping superbugs with a protective coat – CSIRO
Around the world 700,000 people die of drug resistant infections a year, and that figure could rise to 10 million a year by 2050. The resulting financial cost is predicted to reach $100 trillion USD. It’s a global problem…
AdAlta Ltd lists on the ASX
Melbourne-based company, and BioMelbourne Network Member, AdAlta Limited has listed on the ASX. AdAlta is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known…
Australian protein discovery leads to tablet that “melts away blood cancer”
A potent anti-cancer treatment co-developed and trialled in Melbourne has been granted approval for use in patients by the powerful US Food and Drug Administration (FDA). The announcement recognises that the drug, venetoclax, is a successful new therapy…
First 3D map of cell-building protein linked to cancer
Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. The unprecedented view of the protein doublecortin…
First 3D map of cell-building protein linked to cancer
Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. More than one in 10 stomach cancers…
Preparing For Proton Beam Therapy Cancer Boost
Victoria has provided $50 million in funding towards establishing a National Proton Beam Therapy Centre for the treatment of cancer in Melbourne. Minister for Health, Jill Hennessy, made the announcement while touring the construction of University College London…
Study shines new light on programmed cell death
12th August, 2016 A form of regulated cell death known as necroptosis – and its role in health and disease – is the topic of new research by Walter and Eliza Hall Institute scientists. An international team of…
Medtech Trade Mission Going Ahead – Limited Places Still Available!
BioMelbourne Network, on behalf of the State Government of Victoria, is leading a major Medtech Mission to the United States including AdvaMed 2016 – the largest annual medical technology conference on the US calendar. There are still limited…
BioMelbourne Network Members Invited to Meet with International Medtronic Diabetes Representative
US based Medtronic representative, Dr Huzefa Neemuchwala, will be in Melbourne this month. BioMelbourne Network member organisations are invited to meet with Dr Neemuchwala. Interested organisations, please contact Dr Krystal Evans on 9667 6161 Dr Huzefa Neemuchwala, PhD MBA,…
FULLY BOOKED – Free Seminar with Dr Gerald Chan – The Role of Universities in the Innovation Ecosystem
THIS SEMINAR IS FULLY BOOKED The BioMelbourne Network and Biomedical Research Victoria present international guest speaker, Dr Gerald Chan, CEO, Morningside, USA Free Seminar: The Role of Universities in the Innovation Ecosystem With Australia’s changing economy, the role of universities…
Opthea Reports Positive Data from wet AMD Clinical Trial
26th July, 2016 Melbourne, Australia, July 26 2016 – Opthea Limited (ASX:OPT) • Phase 1 dose escalation study met primary objective demonstrating OPT-302 safety and tolerability as monotherapy and in combination with standard of care Lucentis® • Changes…
Stem cells healing broken hearts; Making cancer treatment less aggressive, more effective
The National Stem Cell Foundation of Australia (based in Victoria) supports stem cell science and educates the community about the potential and dangers of stem cell therapies.The winners of the 2016 Metcalf Prizes for Stem Cell Research were…
